Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jul;7(Suppl 3):S95.
doi: 10.21037/atm.2019.04.57.

Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?

Matthew Zibelman  1 , Elizabeth R Plimack  1
Affiliations
Editorial

Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?

Matthew Zibelman et al. Ann Transl Med. 2019 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: M Zibelman, Scientific advisor: EMD Serono, Pfizer; Honoraria: Pfizer; Grants for Clinical Research: BMS, Pfizer, Horizon Pharma. ER Plimack, Scientific Advisor: BMS, Genentech, Incyte, Janssen, Merck, AstraZeneca, Pfizer; Grants for clinical research: Astellas, BMS, Genentech, Merck, Peloton, Pfizer.

Comment on

References

    1. McDermott DF, Motzer RJ, Atkins MB, et al. Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. J Clin Oncol 2016;34:abstr 4507.
    1. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017;390:1853-62. 10.1016/S0140-6736(17)31601-X - DOI - PubMed
    1. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30. 10.1200/JCO.2013.53.0105 - DOI - PMC - PubMed
    1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017;377:1345-56. 10.1056/NEJMoa1709684 - DOI - PMC - PubMed
    1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-90. 10.1056/NEJMoa1712126 - DOI - PMC - PubMed